Home / Resources / Strategic Leadership resources

战略领导力

精选资源

Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat

新闻发布

Upcoming strategic leadership webinars

网络研讨会

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

2026 年 5 月 28 日 – 3-4pm (JST) and 10-11am (CET)

网络研讨会

Controlling Clinical Data from Collection to Submission

2026 年 6 月 3 日 – 12–1PM ET

Popular resources

新闻发布

Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat

新闻发布

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

刊物

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

博客

Data Fabrics in Pharma: Connecting Data for Better Decisions

博客

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

公告

Certara Welcomes Arjun Bedi to its Board of Directors 

在以下活动中与我们的专家会面

会议

Marbach DDI Workshop 2026

May 31 - 2026 年 6 月 2 日

会议

Bio International Convention 2026

2026 年 6 月 22 - 25 日 — 波士顿，马萨诸塞州 — 展位 1304

会议

ISSX 27th North American Meeting

October 11 - 14, 2026 – San Francisco, CA

All Strategic Leadership resources

Controlling Clinical Data from Collection to Submission

Certara Products, Certara Products - GlobalSubmit, Certara Products - Pinnacle 21, Certara.AI, Webinar

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Data Fabrics in Pharma: Connecting Data for Better Decisions

Certara Products, Certara.AI, Drug Development, Blog

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Clinical Pharmacology, Clinical Trials, Drug Development, Drug Safety, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, New Approach Methodologies (NAMs), Blog

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Certara Services, Clinical Pharmacology, Drug Development, Drug Safety, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Blog

Building Trust in Data – Transparency, Traceability, and the Human Element

Certara Products - Pinnacle 21, Clinical Trials, Data Standards, Drug Development, Webinar

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Certara Services, Clinical Trials, Drug Development, Model Informed Drug Development, Model-Based Meta-Analysis (MBMA), Modeling and Simulation, Modeling and Simulation - PK/PD, Therapeutic Specialties, Publication

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Certara Services, Clinical Pharmacology, Drug Development, Drug-Drug Interactions (DDI), Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Conference

Marbach DDI Workshop 2026

Certara Products - Simcyp, Drug-Drug Interactions (DDI), Modeling and Simulation - PBPK, Conference

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Certara Services, Clinical Pharmacology, Clinical Trials, Drug Development, Model Informed Drug Development, Modeling and Simulation, Rare and Neglected Diseases, Blog

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Model Informed Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

Certara Products - Certara IQ, Certara Products - Phoenix, Certara Products - Simcyp, Clinical Pharmacology, Drug Development, Modeling and Simulation, Modeling and Simulation - PBPK, Modeling and Simulation - PK/PD, Modeling and Simulation - QSP, Webinar

1
2
3
……
11
›

订阅时事通讯

为什么订阅？因为改变药物开发不仅是我们的目标，更是我们的执着追求。如果这也是您的想法，那么请第一时间了解新见解，与我们一起推动科学发展。

战略领导力

最新资源

Certara 将参加即将举行的投资者会议

Certara 2026 年第一季度财务业绩报告

Altasciences and Certara Announce Strategic Partnership to Accelerate Early Drug Development

Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat

精选资源

Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat

Upcoming strategic leadership webinars

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Controlling Clinical Data from Collection to Submission

Popular resources

Certara Enters Definitive Agreement for the Sale of its Regulatory Writing and Medical Writing Business to Veristat

Certara to Report First Quarter 2026 Financial Results on May 11th, 2026

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Data Fabrics in Pharma: Connecting Data for Better Decisions

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Certara Welcomes Arjun Bedi to its Board of Directors

在以下活动中与我们的专家会面

Marbach DDI Workshop 2026

Bio International Convention 2026

ISSX 27th North American Meeting

All Strategic Leadership resources

Controlling Clinical Data from Collection to Submission

Integrated Population Pharmacokinetic, Pharmacodynamic, and Safety Analyses to Inform Dosage Selection in the Clinical Development of the ATR Inhibitor Tuvusertib

Data Fabrics in Pharma: Connecting Data for Better Decisions

Regulatory horizons 2026: clinical pharmacology strategy and regulatory expectations

Advancing pharmacoequity through model-informed drug development: Insights from ASCPT 2026

Building Trust in Data – Transparency, Traceability, and the Human Element

Model-Based Meta-Analysis of Objective Response Rate and Survival Endpoints to Compare PD-1 and PD-L1 Treatment Outcomes in Non-Small Cell Lung Cancer

Apotekarsocieteten 临床药理学策略在药物开发中的应用

Marbach DDI Workshop 2026

Rare Disease Day 2026: Accelerating Rare Disease Drug Development Through Cross-Functional Innovation

Maximizing the Impact of Antibody–Drug Conjugates (ADCs): Model-Informed Labeling, Expansion, and Market Access

Optimal Dosing, Optimal Outcomes: Model-Based Approaches for Antibody–Drug Conjugates (ADCs)

订阅时事通讯

快捷链接

解决方案

联系我们